# Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects

> **NCT03721965** · PHASE1,PHASE2 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 2 (actual)

## Conditions studied

- Acute Graft-versus-host Disease

## Interventions

- **DRUG:** Itacitinib
- **DRUG:** Corticosteroids

## Key facts

- **NCT ID:** NCT03721965
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-31
- **Primary completion:** 2020-02-17
- **Final completion:** 2020-02-17
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** The study was terminated due to insufficient efficacy in a separate phase III study
- **Last updated:** 2025-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03721965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03721965, "Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT03721965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*